IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?
XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield.
When comparing the iShares U.S. Pharmaceuticals ETF (IHE) to the State Street SPDR S&P Biotech ETF (XBI), investors are faced with a classic trade-off: the relative stability of large pharmaceutical companies versus the high-growth potential of early-stage biotechnology firms. Both ETFs offer access to medical innovation, but they do so in very different ways.
IHE focuses on well-established pharmaceutical giants that boast steady cash flows, while XBI is more volatile and concentrated in biotech, reacting heavily to clinical trial results and research breakthroughs.
Beta is a key metric used to gauge an ETF's price volatility compared to the broader market, specifically the S&P 500 in this case. Calculated from monthly returns over the fund's existing history (up to five years), beta provides insight into how much an ETF might move in relation to the overall market. The 1-year return shows the total return over the past year, while dividend yield reflects the annual distribution of dividends from the fund's holdings.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
